Pneumonitis associated with bortezomib in a patient with multiple myeloma

Basit Öğe Kaydı
dc.contributor.authorKars, Taha Ulutan
dc.contributor.authorYaskiran, Osman
dc.contributor.authorCeneli, Ozcan
dc.date.accessioned2024-02-23T14:27:03Z
dc.date.available2024-02-23T14:27:03Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractIntroduction Bortezomib, which is widely used in the treatment of multiple myeloma (MM), is a proteasome inhibitor and acts by inducing apoptosis. Bortezomib has many side effects, mainly hematological, neurological, and gastrointestinal. A few cases of bortezomib-induced pneumonitis (BIP) have been reported in the literature. Case Report A 51-year-old male patient who was newly diagnosed with MM received bortezomib, cyclophosphamide, and dexamethasone as first-line therapy. In the first cycle, the patient developed dyspnea, tachypnea, and hypoxia after the fourth day of administration of bortezomib monotherapy according to the treatment protocol. Management and outcome Infection and pulmonary involvement of MM were excluded after radiological evaluations, and a diagnosis of BIP was made. Clinical control was achieved quickly with steroid therapy and oxygen support, and radiological findings improved with treatment. Due to this rare side effect of bortezomib, the treatment regimen containing bortezomib was changed. The patient is still receiving treatment that does not contain bortezomib and does not have any pulmonary problems. Discussion In cancer patients receiving treatment, infection and metastasis should be quickly ruled out when pulmonary problems occur, and drug-induced pneumonitis should be considered. This diagnosis, which often responds dramatically to steroids, has the potential to have serious consequences when not considered. In this case, we present bortezomib-associated pneumonitis, a rare side effect of bortezomib. The most important feature of this case is the development of this side effect at the beginning of the treatment, unlike other cases reported in the literature.en_US
dc.identifier.doi10.1177/10781552221143789
dc.identifier.endpage1024en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue4en_US
dc.identifier.pmid36476141en_US
dc.identifier.scopus2-s2.0-85144412003en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1021en_US
dc.identifier.urihttps://doi.org/10.1177/10781552221143789
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14432
dc.identifier.volume29en_US
dc.identifier.wosWOS:000894553300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBortezomiben_US
dc.subjectPneumonitisen_US
dc.subjectMultiple Myelomaen_US
dc.titlePneumonitis associated with bortezomib in a patient with multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu